HIGH RATES OF ADHERENCE TO BULEVIRTIDE MONOTHERAPY FOR CHRONIC HEPATITIS DELTA THROUGH 96 WEEKS: RESULTS FROM AN INTERIM ANALYSIS OF THE PHASE 3 STUDY MYR301

被引：0
|
作者：
Aleman, Soo
Wedemeyer, Heiner
Brunetto, Maurizia R.
Blank, Antje
Andreone, Pietro
Bogomolov, Pavel
Chulanov, Vladimir
Mamonova, Nina
Geyvandova, Natalia
Morozov, Viacheslav
Sagalova, Olga
Stepanova, Tatyana V.
Da, Ben
Manuilov, Dmitry
Chee, Grace
Li, Mingyang
Lau, Audrey H.
zur Wiesch, Julian Schulze
Cornberg, Markus
Zeuzem, Stefan
Lampertico, Pietro
机构：
来源：
GASTROENTEROLOGY | 2024年 / 166卷 / 05期
关键词：
D O I：
暂无
中图分类号：
R57 [消化系及腹部疾病];
学科分类号：
摘要：
Sa1626
引用
收藏
页码：S1603 / S1604
页数：2
相关论文
共 48 条
  • [21] Bulevirtide monotherapy in patients with chronic HDV : Efficacy and safety results through week 96 from a phase III randomized trial
    Wedemeyer, Heiner
    Aleman, Soo
    Brunetto, Maurizia
    Blank, Antje
    Andreone, Pietro
    Bogomolov, Pavel
    Chulanov, Vladimir
    Mamonova, Nina
    Geyvandova, Natalia
    Morozov, Viacheslav
    Sagalova, Olga
    Stepanova, Tatyana
    Berger, Annemarie
    Ciesek, Sandra
    Manuilov, Dmitry
    Mercier, Renee-Claude
    Da, Ben L.
    Chee, Grace M.
    Li, Mingyang
    Flaherty, John F.
    Lau, Audrey H.
    Osinusi, Anu
    Wiesch, Julian Schulze zur
    Cornberg, Markus
    Zeuzem, Stefan
    Lampertico, Pietro
    JOURNAL OF HEPATOLOGY, 2024, 81 (04)
  • [22] Continued treatment of early virologic nonresponders or partial responders with bulevirtide monotherapy for chronic hepatitis delta leads to improvement in virologic and biochemical responses: Results from an integrated analysis at week 96
    Lampertico, Pietro
    Wedemeyer, Heiner
    Brunetto, Maurizia
    Bogomolov, Pavel
    Stepanova, Tatyana
    Bourliere, Marc
    Fontaine, Helene
    Chee, Grace M.
    Manuilov, Dmitry
    An, Qi
    Freismuth, Aurelie
    Lau, Audrey
    Da, Ben
    Flaherty, John F.
    Mercier, Renee-Claude
    Frenette, Catherine
    Osinusi, Anu
    Gherlan, George Sebastian
    Streinu-Cercel, Adrian
    Zeuzem, Stefan
    Cornberg, Markus
    Roulot, Dominique
    Zoulim, Fabien
    Aleman, Soo
    Asselah, Tarik
    JOURNAL OF GASTROENTEROLOGY AND HEPATOLOGY, 2024, 39 : 102 - 103
  • [23] Treatment with bulevirtide improves patient-reported outcomes in patients with chronic hepatitis delta: An exploratory analysis of a Phase 3 trial at 48 weeks
    Buti, Maria
    Wedemeyer, Heiner
    Aleman, Soo
    Chulanov, Vladimir
    Viacheslav, Morozov
    Sagalova, Olga
    Stepanova, Tatyana
    Gish, Robert G.
    Lloyd, Andrew
    Kaushik, Ankita
    Suri, Vithika
    Manuilov, Dmitry
    Osinusi, Anu
    Flaherty, John F.
    Lampertico, Pietro
    JOURNAL OF HEPATOLOGY, 2022, 77 : S103 - S103
  • [24] BULEVIRTIDE IMPROVES HEALTH RELATED QUALITY LIFE MEASURED BY EQ-5D VAS IN PATIENTS WITH CHRONIC HEPATITIS DELTA: AN EXPLORATORY ANALYSIS OF A PHASE 3 TRIAL AT 48 WEEKS
    Buti, Maria
    Wedemeyer, Heiner
    Aleman, Soo
    Chulanov, Vladimir
    Morozov, Viacheslav
    Sagalova, Olga
    Stepanova, Tatyana
    Gish, Robert G.
    Lloyd, Andrew
    Kaushik, Ankita Modi
    Suri, Vithika
    Manuilov, Dmitry
    Osinusi, Anu O.
    Flaherty, John F.
    Pandey, Shubhram
    Singh, Barinder
    Lampertico, Pietro
    HEPATOLOGY, 2022, 76 : S224 - S225
  • [25] EFFICACY AND SAFETY OF BULEVIRTIDE IN COMBINATION WITH PEGYLATED INTERFERON ALFA-2a IN PATIENTS WITH CHRONIC HEPATITIS DELTA: PRIMARY ENDPOINT RESULTS FROM A PHASE 2b OPEN-LABEL, RANDOMIZED, MULTICENTER STUDY MYR204
    Asselah, Tarik
    Lampertico, Pietro
    Wedemeyer, Heiner
    Streinu-Cercel, Adrian
    Pantea, Victor
    Lazar, Stefan
    Placinta, Gheorghe
    Gherlan, George Sebastian
    Bogomolov, Pavel
    Stepanova, Tatiana
    Morozov, Viacheslav
    Chulanov, Vladimir
    Syutkin, Vladimir E.
    Sagalova, Olga
    Gorodin, Vladmir
    Manuilov, Dmitry
    Mercier, Renee-Claude
    Ye, Lei
    Flaherty, John F.
    Osinusi, Anu O.
    Lau, Audrey H.
    Da, Ben L.
    Bourliere, Marc
    Ratziu, Vlad
    Pol, Stanislas
    Hilleret, Marie-Noelle
    Zoulim, Fabien
    HEPATOLOGY, 2024, 79 (02) : E43 - E44
  • [26] CONTINUED TREATMENT OF EARLY VIROLOGIC NON-RESPONDER OR PARTIAL RESPONDERS WITH BULEVIRTIDE MONOTHERAPY FOR CHRONIC HEPATITIS D LEADS TO IMPROVEMENT IN VIROLOGIC AND BIOCHEMICAL RESPONSES: RESULTS FROM AN INTEGRATED ANALYSIS AT WEEK 96
    Lampertico, Pietro
    Wedemeyer, Heiner
    Brunetto, Maurizia R.
    Bogomolov, Pavel
    Bourliere, Marc
    Fontaine, Helene
    Chee, Grace
    Manuilov, Dmitry
    Lau, Qi An Audrey H.
    Da, Ben L.
    Flaherty, John F.
    Mercier, Renee-Claude
    Frenette, Catherine
    Osinusi, Anu O.
    Sebastian Gherlan, George
    Zeuzem, Stefan
    Cornberg, Markus
    Roulot, Dominique M.
    Zoulim, Fabien
    Aleman, Soo
    Asselah, Tarik
    HEPATOLOGY, 2023, 78 : S67 - S70
  • [27] Efficacy and safety of bulevirtide in combination with pegylated interferon alfa-2a in patients with chronic hepatitis delta: Primary endpoint results from the phase 2b, open-label, randomized, multicenter study MYR204
    Asselah, Tarik
    Lampertico, Pietro
    Wedemeyer, Heiner
    Streinu-Cercel, Adrian
    Pantea, Victor
    Lazar, Stefan
    Placinta, Gheorghe
    Gherlan, George Sebastian
    Bogomolov, Pavel
    Stepanova, Tatyana
    Morozov, Viacheslav
    Chulanov, Vladimir
    Syutkin, Vladimir
    Sagalova, Olga
    Gorodin, Vladimir
    Manuilov, Dmitry
    Mercier, Renee-Claude
    Ye, Lei
    Flaherty, John F.
    Freismuth, Aurelie
    Osinusi, Anu
    Lau, Audrey
    Da, Ben
    Bourliere, Marc
    Ratziu, Vlad
    Pol, Stanislas
    Hilleret, Marie-Noelle
    Zoulim, Fabien
    JOURNAL OF GASTROENTEROLOGY AND HEPATOLOGY, 2024, 39 : 104 - 105
  • [28] Bulevirtide improves health-related quality of life measured by EQ-5D VAS in patients with chronic hepatitis delta: An exploratory analysis of a Phase 3 trial at 48 weeks
    Buti, M.
    Wedemeyer, H.
    Aleman, S.
    Chulanov, V.
    Morozov, V.
    Sagalova, O.
    Stepanova, T.
    Gish, R. G.
    Lloyd, A.
    Kaushik, A. M.
    Suri, V.
    Manuilov, D.
    Osinusi, A. O.
    Flaherty, J.
    Pandey, S.
    Singh, B.
    Lampertico, P.
    DIGESTIVE AND LIVER DISEASE, 2023, 55 : S72 - S73
  • [29] Integrated safety analysis of 24-week data from three phase 2 and one phase 3 clinical trials of bulevirtide monotherapy given at 2 mg and 10 mg dose level for treatment of chronic hepatitis delta
    Lampertico, Pietro
    Aleman, Soo
    Asselah, Tarik
    Bourliere, Marc
    Streinu-Cercel, Adrian
    Bogomolov, Pavel
    Viacheslav, Morozov
    Stepanova, Tatyana
    Lazar, Stefan
    Suri, Vithika
    Manuilov, Dmitry
    Ye, Lei
    Flaherty, John F.
    Osinusi, Anu
    Brunetto, Maurizia
    Wedemeyer, Heiner
    JOURNAL OF HEPATOLOGY, 2022, 77 : S829 - S829
  • [30] Integrated efficacy analysis of 24-week data from two phase 2 and one phase 3 clinical trials of bulevirtide monotherapy given at 2 mg or 10 mg dose level for treatment of chronic hepatitis delta
    Lampertico, Pietro
    Aleman, Soo
    Blank, Antje
    Bogomolov, Pavel
    Chulanov, Vladimir
    Mamonova, Nina
    Viacheslav, Morozov
    Sagalova, Olga
    Stepanova, Tatyana
    Suri, Vithika
    Manuilov, Dmitry
    Ye, Lei
    Flaherty, John F.
    Osinusi, Anu
    Cornberg, Markus
    Brunetto, Maurizia
    Wedemeyer, Heiner
    JOURNAL OF HEPATOLOGY, 2022, 77 : S828 - S828
12345